Brief: Everest Medicines, Providence Therapeutics Jointly Announce Vaccine Development Strategy To Address Omicron (B.1.1.529) Sars-Cov-2 Variant
01/12/2021 24:03
Nov 30 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES AND PROVIDENCE THERAPEUTICS JOINTLY
ANNOUNCE
VACCINE DEVELOPMENT STRATEGY TO ADDRESS OMICRON (B.1.1.529)
SARS-COV-2 VARIANT
Source text for Eikon: ID:nPnc8Q48za
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region